keyboard_arrow_up

General Anxiety Disorder Therapeutic Drugs and Companies Pipeline Review H1 2015

RnRMarketResearch.com adds “General Anxiety Disorder – Pipeline Review, H1 2015” to its store.

The report “General Anxiety Disorder – Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for General Anxiety Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for General Anxiety Disorder and special features on late-stage and discontinued projects.


Complete report is available at http://www.rnrmarketresearch.com/general-anxiety-disorder-pipeline-review-h1-2015-market-report.html .


The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Companies discussed in this General Anxiety Disorder – Pipeline Review, H1 2015 report include   Edgemont Pharmaceuticals, LLC, H. Lundbeck A/S, Pfizer Inc.


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Drug Profiles mentioned in this report are EDG-008, lorazepam ER, PF-06372865, Small Molecule to Modulate Glutamate Receptor for Anxiety Disorders, tedatioxetine,  vortioxetine hydrobromide. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=382512 . (This is a premium report priced at US$2000 for a single user License.)


List of Tables
Number of Products under Development for General Anxiety Disorder, H1 2015 7
Number of Products under Development for General Anxiety Disorder - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Comparative Analysis by Unknown Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
General Anxiety Disorder - Pipeline by Edgemont Pharmaceuticals, LLC, H1 2015 15
General Anxiety Disorder - Pipeline by H. Lundbeck A/S, H1 2015 16
General Anxiety Disorder - Pipeline by Pfizer Inc., H1 2015 17
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Stage and Target, H1 2015 20
Number of Products by Stage and Mechanism of Action, H1 2015 22
Number of Products by Stage and Route of Administration, H1 2015 23
Number of Products by Stage and Molecule Type, H1 2015 24
General Anxiety Disorder Therapeutics - Recent Pipeline Updates, H1 2015 35
General Anxiety Disorder - Dormant Projects, H1 2015 39
General Anxiety Disorder - Discontinued Products, H1 2015 40

List of Figures
Number of Products under Development for General Anxiety Disorder, H1 2015 7
Number of Products under Development for General Anxiety Disorder - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 11
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Top 10 Targets, H1 2015 19
Number of Products by Stage and Top 10 Targets, H1 2015 20
Number of Products by Top 10 Mechanism of Actions, H1 2015 21
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 22
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 23
Number of Products by Stage and Top 10 Molecule Types, H1 2015 24


Explore more reports on Mental Illness Drugs at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/mental-illness-drugs .